Communiqués Arvinas, Inc.

Actions

ARVN

US04335A1051

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:00:42 07/10/2026			Varia. 5j.	Varia. 1 janv.
7,420 ^USD	+1,50%		-3,81%	-37,27%

20:21	Arvinas, Inc. présente de nouvelles données issues de l’essai clinique de phase 1 d’ARV-102 chez des patients atteints de la maladie de Parkinson	CI
28/09	Arvinas, Inc. annonce l’administration de la première dose à un participant dans son essai clinique de phase 1/2 d’ARV-6723	CI

Communiqués

13:00	Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease	GL
01/10	Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®	GL
29/09	Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
29/09	Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate	AQ
28/09	Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate	GL
03/09	Arvinas to Participate in Upcoming Investor Conferences	GL
01/09	Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
05/08	Arvinas : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
04/08	Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update	GL
28/07	Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026	GL
05/06	Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease	AQ
04/06	Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease	GL
04/06	Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease	AQ
29/05	Arvinas to Present at Jefferies Global Healthcare Conference	GL
18/05	Arvinas Employees Give Back During Company-wide Impact Day	GL
12/05	Arvinas : Corporate Presentation – May 2026	PU
12/05	Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update	GL
12/05	Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)	GL
05/05	Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026	GL
01/05	Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer	GL
18/03	Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days	GL
12/03	Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	AQ
11/03	Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders	GL
24/02	Arvinas : Corporate Presentation – February 2026	PU
24/02	Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	GL